Subscribe

LSPN Spring North America 2025

The 7th Annual LSPN North America–Spring Conference took place at The Hyatt Regency Boston on 6-7 May 2025, bringing together leading IP professionals from the pharmaceutical, biotechnology, and medtech sectors.

This essential event offered expert sessions, interactive panels, and roundtables focused on the latest legal developments and practical strategies shaping life sciences IP. With a strong presence of in-house counsel, the conference provided a unique opportunity to connect with peers and gain insights into patentability, prosecution, litigation, and more.

Brought to you by Life Sciences Intellectual Property Review, LSPN remains the premier event for those navigating life sciences IP challenges. Watch videos below featuring speakers from organisations such as BlueRock Therapeutics, Merck, BioNTech, Pfizer, and Radius Health.

WATCH: Section 112 – Where has the dust settled?
WATCH: Section 112 – Where has the dust settled?
David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v. Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied – and how it may continue to be applied – by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector.